Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.


Journal

Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885

Informations de publication

Date de publication:
12 2022
Historique:
pubmed: 14 9 2022
medline: 28 10 2022
entrez: 13 9 2022
Statut: ppublish

Résumé

Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD IgG levels, neutralizing antibody titres against 19A, Delta and Omicron isolates, as well as IFN-γ release following cell stimulation with SARS-CoV-2 peptides. We reported that two weeks after diagnosis a greater proportion of HCWs infected with 20A (78.9%, 15/19) than with Omicron BA.1 (44.7%, 17/38; p = 0.02) were still positive by RT-qPCR. We found that Omicron breakthrough infections led to an overall enhancement of vaccine-induced humoral and cellular immunity as soon as a median [interquartile range] of 8 [7-9] days post symptom onset. Among samples with similar high viral loads, non-culturable samples exhibited higher neutralizing antibody titres and anti-RBD IgG levels than culturable samples. Additionally, Omicron infection led to an enhancement of antibodies neutralization capacity against other SARS-CoV-2 isolates. Taken together, the results suggest that Omicron BA.1 vaccine breakthrough infection is associated with a faster viral clearance than that of the ancestral SARS-CoV-2, in addition this new variant leads to a rapid enhancement of the humoral response against multiple SARS-CoV-2 variants, and of the cellular response.

Identifiants

pubmed: 36098494
doi: 10.1080/22221751.2022.2122578
pmc: PMC9621261
doi:

Substances chimiques

Antibodies, Viral 0
Viral Vaccines 0
Immunoglobulin G 0
Antibodies, Neutralizing 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2423-2432

Références

Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Nature. 2022 Jul;607(7918):356-359
pubmed: 35523247
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
J Travel Med. 2022 May 31;29(3):
pubmed: 35262737
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Clin Chem. 2021 Apr 29;67(5):742-752
pubmed: 33399823
N Engl J Med. 2022 Jul 21;387(3):275-277
pubmed: 35767428
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Eur J Immunol. 2021 Dec;51(12):3239-3242
pubmed: 34387859
Sci Rep. 2021 Jul 22;11(1):14977
pubmed: 34294751
JAMA Netw Open. 2022 May 2;5(5):e2213606
pubmed: 35608859
Nat Commun. 2022 Oct 23;13(1):6316
pubmed: 36274062
BMJ Open. 2020 Nov 24;10(11):e041268
pubmed: 33234651
Clin Microbiol Infect. 2020 Jul;26(7):960-962
pubmed: 32234449
Nat Med. 2022 Jul;28(7):1491-1500
pubmed: 35395151

Auteurs

Carla Saade (C)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Karen Brengel-Pesce (K)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Alexandre Gaymard (A)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

Mary-Anne Trabaud (MA)

Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

Gregory Destras (G)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Guy Oriol (G)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Valérie Cheynet (V)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Marion Debombourg (M)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Bouchra Mokdad (B)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Geneviève Billaud (G)

Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

Antoine Oblette (A)

Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Hervé Créhalet (H)

Mirialis - Biogroup Auvergne Rhône alpes, Cluses, France.

Jean-Marc Giannoli (JM)

Dyomédéa-BIOGROUP - Plateau technique de la Sauvegarde, Lyon, France.

Christine Garrigou (C)

Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

Laurence Generenaz (L)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

Christelle Compagnon (C)

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.

André Boibieux (A)

Infectious and Tropical Diseases Unit, Hospices Civil de Lyon, Lyon, France.

Bruno Lina (B)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Florence Morfin (F)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Bruno Pozzetto (B)

Team GIMAP, CIRI-Centre International de Recherche en Infectiologie, Université Jean Monnet de Saint-Etienne, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, Saint-Etienne, France.
Laboratoire des Agents Infectieux, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France.

Laurence Josset (L)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Sophie Trouillet-Assant (S)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

Antonin Bal (A)

CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH